IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen’s 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am Eastern Time (7:30 am Pacific Time). A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, an ...

Core Viewpoint - Beta Bionics, Inc. reported strong financial results for Q4 and full year 2025, indicating significant growth in the durable insulin pump market and providing guidance for 2026 [1][5][12]. Financial Highlights Fourth Quarter 2025 - Net sales reached $32.1 million, a 57% increase from $20.4 million in Q4 2024 [5][21]. - Durable Medical Equipment (DME) channel net sales were $22.3 million, up 24% from $18.0 million in Q4 2024 [5][21]. - Pharmacy Benefit Plan (PBP) channel net sales surged to $9.8 million, a 295% increase from $2.5 million in Q4 2024 [5][21]. - Gross margin improved to 59.0%, up 179 basis points from 57.2% in Q4 2024 [5][21]. - The installed customer base grew to 35,011 users, a 129% increase from 15,298 in Q4 2024 [5][21]. - New patient starts totaled 5,592, a 37% increase from 4,084 in Q4 2024 [5][26]. Full Year 2025 - Total net sales for the year were $100.3 million, a 54% increase from $65.1 million in 2024 [5][21]. - DME channel net sales for the year were $75.8 million, up 29% from $58.8 million in 2024 [5][21]. - PBP channel net sales reached $24.4 million, a 287% increase from $6.3 million in 2024 [5][21]. - Gross margin for the year was 55.4%, up 29 basis points from 55.1% in 2024 [5][21]. - New patient starts for the year totaled 19,713, a 52% increase from 12,994 in 2024 [5][26]. Strategic Highlights - The company completed its first-in-human Phase 2a feasibility trial for its bihormonal system in New Zealand [5][6]. - An additional Phase 2a feasibility trial is expected to be initiated in the first half of 2026 [5][6]. - The company aims to progress to Phase 2b following the completion of the Phase 2a trial, which is anticipated to be a pivotal trial [5][6]. 2026 Guidance - Estimated total revenue for 2026 is projected to be approximately $130 million to $135 million [12]. - Expected gross margin for 2026 is estimated to be between 55.5% and 57.5% [12]. - The company anticipates that 36% to 38% of new patient starts will be reimbursed through the PBP channel [12].

Core Insights - Insulet Corporation specializes in innovative diabetes management solutions, particularly known for its Omnipod Insulin Management System, a tubeless, wearable pump that delivers continuous insulin for up to three days [1][2] Company Overview - Insulet is headquartered in Acton, Massachusetts, and operates globally, leveraging advanced manufacturing for scalable production and research and development [2] - The company has a market capitalization of $20 billion [2] Financial Performance - Insulet is expected to report a profit of $1.48 per share for Q4 fiscal 2025, representing a 28.7% year-over-year growth [4] - For the full fiscal year 2025, analysts anticipate Insulet's diluted EPS to grow by 50.9% to $4.89, followed by a 26.4% increase to $6.18 in fiscal 2026 [4] Stock Performance - Over the past 52 weeks, Insulet's stock has gained 3.2%, while the S&P 500 Index has increased by 13.7% during the same period, indicating underperformance [5] - The stock gained 2.9% intraday on November 6, 2025, following better-than-expected third-quarter results, with revenue increasing by 29.9% year-over-year to $706.30 million [6] - Insulet's total Omnipod revenue rose by 31% to $699.20 million, and its non-GAAP EPS increased by 37.8% to $1.24 [6] Guidance - Based on recent growth, the company raised its fiscal 2025 revenue guidance from a growth range of 24%-27% to 28%-29% [6]

Core Insights - Trinity Biotech is advancing its mission to deliver next-generation diabetes management solutions and expand its global market penetration, particularly in the $2 billion+ HbA1c market [1][2] Company Developments - Trinity Biotech has secured regulatory clearances in multiple countries for its next-generation high-capacity HbA1c column system for the Premier Hb9210 analyzer, which is now available in over 10 countries, including the United States [1] - The upgraded column system enhances testing throughput by up to four times compared to the existing system, reduces instrument downtime, and minimizes maintenance requirements, leading to improved operational efficiency [3][7] - The Premier Hb9210 solution is recognized as a gold standard in HbA1c testing, with strong clinical performance confirmed by peer-reviewed studies [3] Market Potential - The global laboratory HbA1c market is currently valued at over $2 billion and is projected to exceed $3.5 billion by 2030, driven by the increasing prevalence of diabetes [2] - The launch of the advanced system in key markets positions Trinity Biotech to capture further growth opportunities in the global diabetes care segment [3] Operational Efficiency - The new column system's operational gains create a more efficient workflow for clinical laboratories, supporting broader adoption of the platform [3] - The latest software update enhances automation of routine tasks, enabling greater productivity and cost savings [7]

Core Insights - Beta Bionics, Inc. plans to release its third quarter 2025 financial results on October 28, 2025, after market close [1] - A conference call and webcast will be held on the same day at 4:30 pm Eastern Time [1] Company Overview - Beta Bionics is a commercial-stage medical device company focused on developing innovative solutions for insulin-requiring individuals with diabetes [2] - The company utilizes advanced adaptive closed-loop algorithms to enhance diabetes treatment [2] - The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines insulin doses, aiming to improve health outcomes for a wide range of diabetes patients [2]